Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820256 | 0.98 | STAT3 (0.35) | STAT3STAT1 | |
| SCHEMBL25612 | 0.98 | STAT3 (0.35) | STAT3STAT1 | |
| Hydrochloric Acid SCHEMBL8403409 | 0.96 | STAT3 (0.34) | STAT3STAT1 | |
| SCHEMBL670040 | 0.96 | STAT3 (0.34) | STAT3STAT1 | |
| SCHEMBL1684236 | 0.96 | STAT3 (0.34) | STAT3STAT1 | |
| SCHEMBL15874559 | 0.96 | STAT3 (0.34) | STAT3STAT1 | |
| SCHEMBL6411978 | 0.96 | STAT3 (0.37) | STAT3STAT1 | |
| SCHEMBL6418524 | 0.96 | STAT3 (0.37) | STAT3STAT1 | |
| SCHEMBL3248276 | 0.96 | STAT3 (0.34) | STAT3STAT1 | |
| SCHEMBL13584886 | 0.94 | STAT3 (0.33) | STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094292-A1 | Photoactivatable Antimicrobial Agents And Therapeutic And Diagnostic Methods Of Using Same | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | claimed |
| US-20160073634-A1 | BETA-LACTAMASE TARGETED PHOTOSENSITIZER FOR PESTICIDE AND PEST DETECTION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-03-17 | — | — | US | claimed |
| US-8703427-B2 | Biological materials and uses thereof | PHOTOBIOTICS LIMITED (GB) | 2014-04-22 | — | — | US | claimed |
| WO-2013192521-A1 | β-LACTAMASE TARGETED PHOTOSENSITIZER FOR PESTICIDE AND PEST DETECTION | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-27 | — | — | WO | claimed |
| EP-2285381-A2 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS AND THERAPEUTIC AND DIAGNOSTIC METHODS OF USING SAME | The General Hospital Corporation (US) | 2011-02-23 | — | — | EP | claimed |
| US-20100016208-A1 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2010-01-21 | — | — | US | claimed |
| US-20090304803-A1 | Compositions and methods relating to target-specific photodynamic therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2009-12-10 | — | — | US | claimed |
| WO-2009137062-A2 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS AND THERAPEUTIC AND DIAGNOSTIC METHODS OF USING SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2009-11-12 | — | — | WO | claimed |
| EP-1962833-A2 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007059226-A2 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2007-05-24 | — | — | WO | claimed |
| WO-2006133271-A2 | COMPOSITIONS AND METHODS RELATING TO TARGET-SPECIFIC PHOTODYNAMIC THERAPY | THE GENERAL HOSPITAL CORPORATION (US) | 2006-12-14 | — | — | WO | claimed |
| US-20020197262-A1 | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | claimed |
| WO-2002100326-A2 | PHOTOIMMUNOTHERAPIES FOR CANCER USING PHOTOSENSITIZER IMMUNOCONJUGATES AND COMBINATION THERAPIES | THE GENERAL HOSPITAL CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-11998266-B2 | Intravascular energy delivery | OTSUKA MEDICAL DEVICES CO., LTD (JP) | 2024-06-04 | — | — | US | disclosed |
| US-20240139540-A1 | LIGHT-BASED SYSTEM AND METHOD FOR SHAPING AND TREATING HAIR | THE GENERAL HOSPITAL CORPORATION (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240033347-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| WO-2003003975-A2 | DETECTION AND THERAPY OF VULNERABLE PLAQUE WITH PHOTODYNAMIC COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-20020197262-A1 | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| WO-2002100326-A2 | PHOTOIMMUNOTHERAPIES FOR CANCER USING PHOTOSENSITIZER IMMUNOCONJUGATES AND COMBINATION THERAPIES | THE GENERAL HOSPITAL CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020187935-A1 | Photochemical tissue bonding | AURA MEDSYSTEMS, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160073634-A1 | BETA-LACTAMASE TARGETED PHOTOSENSITIZER FOR PESTICIDE AND PEST DETECTION | DDT, BCHE, GUSB | STAT3 4740/4885STAT1 4162/4885 |
| US-20100016208-A1 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS | CRY1, HMBS, PPOX | STAT3 1242/4885STAT1 268/4885 |
| US-20180094292-A1 | Photoactivatable Antimicrobial Agents And Therapeutic And Diagnostic Methods Of Using Same | HMBS, GUSB, LCT | STAT3 4491/4885STAT1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.